v3.23.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 160,257 $ 101,808
Acquired in-process research and development 10,000 0
General and administrative 48,019 54,225
Total operating expenses 218,276 156,033
Interest income, net (7,578) 0
Other expense 253 781
Loss before provision (benefit) for income taxes (210,951) (156,814)
Provision (benefit) for income taxes 9 (84)
Net loss $ (210,960) $ (156,730)
Net loss per common share - basic (in dollars per share) $ (1.71) $ (1.43)
Net loss per common share - diluted (in dollars per share) $ (1.71) $ (1.43)
Weighted-average common shares outstanding – basic (in shares) 123,075,329 109,679,256
Weighted-average common shares outstanding – diluted (in shares) 123,075,329 109,679,256

Source